12 stories tagged Drug Discovery
OpenAI has acquired Orchestra Bio to integrate AI-powered operations into life sciences R&D, helping biopharma teams accelerate drug development and advance new treatments.
Anthropic has quietly established a biology lab to advance its AI-driven drug discovery program, enabling the company to test AI-generated hypotheses in real-world biological systems and potentially speed up the development of new treatments.
César de la Fuente's lab at the University of Pennsylvania uses OpenAI's Codex and ChatGPT to search living and extinct genomes for antimicrobial candidates, accelerating the fight against drug-resistant infections.
Google DeepMind's AlphaFold 3 is helping scientists design new medicines faster by predicting protein structures and interactions. This breakthrough could accelerate treatments for Alzheimer's, cancer, and other hard-to-target diseases.
Researchers propose a modular Context-Augmented Prompting framework that combines small language models (SLMs) with graph neural networks (GNNs) to overcome structural blindness in molecular property prediction. The method provides predictive hints and explanatory subgraphs at inference time, improving accuracy for drug discovery and materials science.
OpenAI researcher Miles Wang is in funding talks for a new AI drug discovery startup, with discussions valuing the company at $2 billion. The move underscores surging investor interest in applying AI to accelerate life-saving drug development.
Anthropic introduced Claude Science, an AI workbench for scientists that consolidates fragmented tools and datasets into one environment, helping to streamline drug development. The move expands Anthropic's reach beyond coding into scientific research.
OpenAI and Molecule.one demonstrated a near-autonomous AI chemist using GPT-5.4 that optimized a key reaction in medicinal chemistry. This breakthrough could accelerate drug development by autonomously planning, executing, and analyzing experiments.
Researchers developed a new AI system called ATOM that uses multiple specialized agents to explore different paths for designing molecules. This could lead to faster discovery of new drugs and materials by balancing conflicting goals more effectively.
Researchers introduce MolClaw, an autonomous AI agent that excels in drug molecule evaluation, screening, and optimization. The agent uses a three-tier hierarchical skill architecture to unify over 30 specialized tools, addressing key challenges in computational drug discovery.
10x Science has secured $4.8 million to help researchers navigate the overwhelming number of AI-generated drug candidates. The startup aims to streamline pharmaceutical R&D by identifying the most promising molecules.
OpenAI has introduced GPT-Rosalind, a specialized AI model designed to enhance drug discovery, genomics analysis, and protein reasoning. This model aims to accelerate scientific research workflows in the life sciences sector.